Figure 5.

Demonstrating efficacy of new VDA in tumors growing in mice. (a) MDA-MB-231-luc breast tumor response to OXi8007 treatment (350 mg/kg IP) assessed by BLI at 4, 24, 48 and 72 h after treatment. BLI intensity images overlaid on photos of mice. Corresponding signal intensity curves at right; (b) similarly, orthotopic RENCA-luc kidney tumor bearing mouse at baseline, 4 and 24 h. Dynamic time course intensity traces are shown for each time following administration of luciferin. At 4 and 24 h there was an approximately 80% reduction in light emission corresponding to vascular shutdown and matching the MSOT observation in Figure 10; (c) BLI as predictive imaging biomarker. For groups of MDA-MB-231-luc tumors (control, low and high dose OXi8007 as well as combination with carboplatin) there was a strong correlation between the signal shutdown at 4 h after administering VDA and the tumor growth over the next 7 days (R² > 0.8).